RTP Mobile Logo
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Breast Cancer
Released May 2013

Roundtable participants include Drs Adam M Brufsky, Lisa A Carey, William J Gradishar, Sara A Hurvitz, Monica Morrow, Ruth O’Regan, Edith A Perez and Hope S Rugo. (Audio Content)

CE Disclosures and Faculty Information

  • OVERVIEW OF ACTIVITY
    Breast cancer is one of the most rapidly evolving fields in medical oncology. Published results from ongoing clinical trials lead to the continuous emergence of new therapeutic agents and changes in the indications for existing treatments. In order to offer optimal patient care — including the option of clinical trial participation — clinicians must be well informed of these advances. To bridge the gap between research and practice, this program features leading oncology investigators debating the merits, applications and limitations of emerging data sets. By providing access to the latest research developments and expert perspectives, this CME program assists medical oncologists, hematologists and hematology-oncology fellows with the formulation of up-to-date clinical management strategies.

    LEARNING OBJECTIVES

    • Appropriately use biomarkers to assess risk and individualize therapeutic decision-making for patients with early breast cancer.
    • Develop evidence-based treatment approaches for patients diagnosed with HER2-positive breast cancer in the neoadjuvant, adjuvant and metastatic settings.
    • Formulate individualized approaches to later-line therapy for patients with HER2-negative metastatic breast cancer.
    • Assimilate new clinical trial evidence evaluating the use of mTOR inhibition to reverse endocrine resistance into the therapeutic algorithm for patients with progressive ER-positive metastatic breast cancer.
    • Evaluate recently presented data supporting the extended use of adjuvant tamoxifen beyond 5 years for patients with ER-positive early breast cancer and, where appropriate, integrate these findings into clinical practice.
    • Counsel appropriately selected patients with breast cancer about participation in ongoing clinical trials.

    ACCREDITATION STATEMENT
    Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

    CREDIT DESIGNATION STATEMENT
    Research To Practice designates this enduring material for a maximum of 2.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    HOW TO USE THIS CME ACTIVITY
    This CME activity contains audio component. To receive credit, the participant should review the CME information, listen to the audio MP3s, complete the Post-test with a score of 70% or better and fill out the Educational Assessment and Credit Form located on our website at ResearchToPractice.com/BCUTT113/CME. The text portion of this activity contains edited comments, clinical trial schemas, graphics and references that supplement the audio MP3s, as well as links to relevant full-text articles, abstracts, trial information and other web resources.

    CONTENT VALIDATION AND DISCLOSURES
    Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess potential conflicts of interest with faculty, planners and managers of CME activities. Real or apparent conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.

    FACULTYDrs Gradishar and Morrow had no real or apparent conflicts of interest to report. The following faculty (and their spouses/partners) reported real or apparent conflicts of interest, which have been resolved through a conflict of interest resolution process: Dr BrufskyAdvisory Committee: Roche Laboratories Inc; Consulting Agreements: Celgene Corporation, Genentech BioOncology, Genomic Health Inc, Novartis Pharmaceuticals Corporation; Speakers Bureau: Celgene Corporation, Genentech BioOncology, Novartis Pharmaceuticals Corporation. Dr CareyAdvisory Committee, Consulting Agreements and Speakers Bureau: Amgen Inc, Bristol-Myers Squibb Company, Genentech BioOncology, Novartis Pharmaceuticals Corporation, Pfizer Inc, Sanofi; Research Support: Genentech BioOncology, GlaxoSmithKline, Sanofi. Dr HurvitzContracted Research: Boehringer Ingelheim Pharmaceuticals Inc, Eisai Inc, Genentech BioOncology, GlaxoSmithKline, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi; Paid Travel: Novartis Pharmaceuticals Corporation. Dr O’ReganAdvisory Committee: Celgene Corporation, Novartis Pharmaceuticals Corporation; Consulting Agreements: Novartis Pharmaceuticals Corporation, Roche Laboratories Inc; Contracted Research: Genentech BioOncology. Dr PerezContracted Research: Genentech BioOncology, Genomic Health Inc, GlaxoSmithKline. Dr RugoPaid Research: Bristol-Myers Squibb Company, Celgene Corporation, Genentech BioOncology, GlaxoSmithKline, ImClone Systems, a wholly owned subsidiary of Eli Lilly and Company, Novartis Pharmaceuticals Corporation, Roche Laboratories Inc, Sanofi.

    EDITORDr Love is president and CEO of Research To Practice, which receives funds in the form of educational grants to develop CME activities from the following commercial interests: AbbVie Inc, Algeta US, Allos Therapeutics, Amgen Inc, ArQule Inc, Astellas, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, Biodesix Inc, Biogen Idec, Boehringer Ingelheim Pharmaceuticals Inc, Bristol-Myers Squibb Company, Celgene Corporation, Daiichi Sankyo Inc, Dendreon Corporation, Eisai Inc, EMD Serono Inc, Foundation Medicine Inc, Genentech BioOncology, Genomic Health Inc, Gilead Sciences Inc, Incyte Corporation, Lilly USA LLC, Medivation Inc, Merck, Millennium: The Takeda Oncology Company, Mundipharma International Limited, Novartis Pharmaceuticals Corporation, Onyx Pharmaceuticals Inc, Prometheus Laboratories Inc, Regeneron Pharmaceuticals, Sanofi, Seattle Genetics, Spectrum Pharmaceuticals Inc and Teva Oncology.

    RESEARCH TO PRACTICE STAFF AND EXTERNAL REVIEWERS — The scientific staff and reviewers for Research To Practice have no real or apparent conflicts of interest to disclose.

    This educational activity contains discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.

    This activity is supported by educational grants from AbbVie Inc, Eisai Inc, Genentech BioOncology, Genomic Health Inc and Novartis Pharmaceuticals Corporation.

    Hardware/Software Requirements:
    A high-speed Internet connection
    A monitor set to 1280 x 1024 pixels or more
    Internet Explorer 7 or later, Firefox 3.0 or later, Chrome, Safari 3.0 or later
    Adobe Flash Player 10.2 plug-in or later
    Adobe Acrobat Reader
    (Optional) Sound card and speakers for audio
    A high-speed Internet connection

    Last review date: May 2013
    Expiration date: May 2014

    After completing the Post-test, learners may download and review the answers here in order to identify further areas of study.

Acknowledge and close

Listen to audio:
Current Controversies, Recent Developments and Emerging Strategies in the Practical Management of Breast Cancer
Released May 2013

Roundtable participants include Drs Adam M Brufsky, Lisa A Carey, William J Gradishar, Sara A Hurvitz, Monica Morrow, Ruth O’Regan, Edith A Perez and Hope S Rugo. (Audio Content)

Read print: